NASDAQ:NVCR - NovoCure Stock Price, Price Target & More

$24.65 -0.35 (-1.40 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$24.65
Today's Range$24.55 - $25.50
52-Week Range$10.50 - $25.70
Volume1.26 million shs
Average Volume1.04 million shs
Market Capitalization$2.23 billion
P/E Ratio-35.21
Dividend YieldN/A
Beta3.16

About NovoCure (NASDAQ:NVCR)

NovoCure logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Debt-to-Equity Ratio0.86%
Current Ratio4.88%
Quick Ratio4.44%

Price-To-Earnings

Trailing P/E Ratio-35.21
Forward P/E Ratio-49.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.03 million
Price / Sales12.59
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book19.41

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-34.83%
Return on Equity-51.74%
Return on Assets-23.51%

Miscellaneous

Employees495
Outstanding Shares90,400,000

How to Become a New Pot Stock Millionaire

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

How were NovoCure's earnings last quarter?

NovoCure (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical equipment provider earned $53.66 million during the quarter, compared to the consensus estimate of $53.17 million. NovoCure had a negative net margin of 34.83% and a negative return on equity of 51.74%. The company's quarterly revenue was up 77.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) EPS. View NovoCure's Earnings History.

When is NovoCure's next earnings date?

NovoCure is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for NovoCure.

What price target have analysts set for NVCR?

5 equities research analysts have issued 1 year price targets for NovoCure's shares. Their predictions range from $14.00 to $32.00. On average, they expect NovoCure's share price to reach $21.00 in the next twelve months. View Analyst Ratings for NovoCure.

What are Wall Street analysts saying about NovoCure stock?

Here are some recent quotes from research analysts about NovoCure stock:
  • 1. Mizuho analysts commented, "We now anticipate a potential FDA approval for the mesothelioma indication before year-end 2018 given the company’s filing under Humanitarian Device Exemption. We updated our model to reflect revenues from mesothelioma in the coming years and raise our PT to $32." (4/18/2018)
  • 2. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (2/28/2018)
  • 3. JPMorgan Chase analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)

Who are some of NovoCure's key competitors?

Who are NovoCure's key executives?

NovoCure's management team includes the folowing people:
  • Mr. William F. Doyle, Exec. Chairman (Age 56)
  • Mr. Asaf Danziger, CEO & Director (Age 52)
  • Mr. Kinyip Gabriel Leung, Vice Chairman & Chairman of the Global Commercialization Team (Age 56)
  • Prof. Yoram Palti, Founder, CTO & Director (Age 80)
  • Mr. Wilhelmus C. M. Groenhuysen, CFO & Principal Accounting Officer (Age 60)

Has NovoCure been receiving favorable news coverage?

Media headlines about NVCR stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovoCure earned a news impact score of 0.15 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 45.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $24.65.

How big of a company is NovoCure?

NovoCure has a market capitalization of $2.23 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. NovoCure employs 495 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for NovoCure (NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NovoCure (NASDAQ:NVCR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for NovoCure in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible downside of 14.81%. The high price target for NVCR is $32.00 and the low price target for NVCR is $14.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.862.862.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$21.2857$20.8571$20.1429
Price Target Upside: 14.81% downside6.56% upside6.41% upside3.83% upside

NovoCure (NASDAQ:NVCR) Consensus Price Target History

Price Target History for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ:NVCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018Deutsche BankUpgradeHold -> Buy$23.80 -> $19.00LowView Rating Details
4/18/2018MizuhoReiterated RatingBuy -> Buy$28.00 -> $32.00HighView Rating Details
11/20/2017JPMorgan ChaseReiterated RatingBuyN/AView Rating Details
10/27/2017WedbushReiterated RatingOutperform$29.00 -> $25.00N/AView Rating Details
5/24/2017Wells FargoUpgradeMarket Perform -> Outperform$15.00HighView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
7/29/2016BarclaysLower Price TargetUnderweight$12.00 -> $9.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

NovoCure (NASDAQ:NVCR) Earnings History and Estimates Chart

Earnings by Quarter for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ:NVCR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.22)($0.22)($0.22)

NovoCure (NASDAQ NVCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018($0.12)N/AView Earnings Details
2/22/2018Before Market($0.14)($0.12)$53.17 million$53.66 millionViewListenView Earnings Details
10/26/20179/30/2017($0.20)($0.13)$43.45 million$50.10 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.23)($0.24)$42.20 million$38.38 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.32)$2.54$17.85 million$12.38 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NovoCure (NASDAQ:NVCR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NovoCure (NASDAQ NVCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 42.83%
Insider Trading History for NovoCure (NASDAQ:NVCR)
Institutional Ownership by Quarter for NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ NVCR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Michael J AmbrogiCOOSell40,000$23.03$921,200.00166,558View SEC Filing  
4/18/2018Yoram PaltiInsiderSell44,072$23.65$1,042,302.80116,451View SEC Filing  
4/3/2018Yoram PaltiInsiderSell60,000$20.32$1,219,200.00View SEC Filing  
3/29/2018Yoram PaltiCTOSell30,000$21.67$650,100.00View SEC Filing  
2/23/2018Michael J AmbrogiCOOSell8,458$19.83$167,722.14105,288View SEC Filing  
2/23/2018Todd Christopher LongsworthGeneral CounselSell6,591$19.83$130,699.5326,665View SEC Filing  
2/23/2018Wilhelmus Cm GroenhuysenCFOSell13,351$19.83$264,750.33252,412View SEC Filing  
1/29/2018Asaf DanzigerCEOSell13,974$24.02$335,655.48356,790View SEC Filing  
1/29/2018Todd Christopher LongsworthGeneral CounselSell11,630$24.00$279,120.0016,628View SEC Filing  
1/24/2018Asaf DanzigerCEOSell20,848$22.10$460,740.80387,820View SEC Filing  
1/16/2018Asaf DanzigerCEOSell14,900$22.20$330,780.00398,068View SEC Filing  
1/12/2018Asaf DanzigerCEOSell336,420$22.33$7,512,258.60435,863View SEC Filing  
1/11/2018Eilon D KirsonInsiderSell25,320$22.00$557,040.003,181View SEC Filing  
1/9/2018Wilhelmus Cm GroenhuysenCFOSell31,132$21.02$654,394.64240,210View SEC Filing  
1/4/2018Wilhelmus Cm GroenhuysenCFOSell28,868$21.03$607,094.04268,568View SEC Filing  
11/13/2017Yoram PaltiInsiderSell30,000$17.13$513,900.00View SEC Filing  
11/9/2017Yoram PaltiCTOSell30,000$18.25$547,500.00View SEC Filing  
11/7/2017Yoram PaltiInsiderSell60,000$21.06$1,263,600.00View SEC Filing  
11/6/2017Asaf DanzigerCEOSell6,919$22.00$152,218.00View SEC Filing  
11/3/2017Asaf DanzigerCEOSell2,300$22.00$50,600.00756,024View SEC Filing  
11/3/2017Eilon D KirsonInsiderSell3,400$22.00$74,800.0040,701View SEC Filing  
11/3/2017Michael J AmbrogiCOOSell1,200$22.00$26,400.0024,987View SEC Filing  
11/2/2017Yoram PaltiCTOSell30,000$21.78$653,400.00View SEC Filing  
11/1/2017Asaf DanzigerCEOSell15,866$22.01$349,210.66774,040View SEC Filing  
11/1/2017Eilon D KirsonInsiderSell22,269$22.01$490,140.6963,120View SEC Filing  
11/1/2017Michael J AmbrogiCOOSell24,327$22.01$535,437.2749,514View SEC Filing  
9/25/2017Asaf DanzigerCEOSell900$22.05$19,845.00774,190View SEC Filing  
9/14/2017Asaf DanzigerCEOSell37,272$22.01$820,356.72776,862View SEC Filing  
9/13/2017Asaf DanzigerCEOSell35,500$22.01$781,355.00776,862View SEC Filing  
7/11/2017Asaf DanzigerCEOSell7,383$19.95$147,290.85462,765View SEC Filing  
7/10/2017Asaf DanzigerCEOSell274,359$18.07$4,957,667.13668,865View SEC Filing  
7/6/2017Asaf DanzigerCEOSell160,138$18.14$2,904,903.32899,462View SEC Filing  
7/5/2017Asaf DanzigerCEOSell155,088$18.14$2,813,296.32899,462View SEC Filing  
6/26/2017Pomona Capital Vii Fund InvestMajor ShareholderSell1,072,532$17.35$18,608,430.20View SEC Filing  
6/21/2017Eilon D KirsonInsiderSell66,361$16.78$1,113,537.58222,722View SEC Filing  
6/19/2017Asaf DanzigerCEOSell124,720$15.51$1,934,407.20896,917View SEC Filing  
6/19/2017Eilon D KirsonInsiderSell15,000$15.06$225,900.00289,083View SEC Filing  
6/16/2017Asaf DanzigerCEOSell42,457$15.15$643,223.551,030,849View SEC Filing  
6/14/2017Asaf DanzigerCEOSell94,102$15.22$1,432,232.441,069,496View SEC Filing  
6/12/2017Asaf DanzigerCEOSell180,601$15.13$2,732,493.131,163,296View SEC Filing  
6/12/2017Eilon D KirsonInsiderSell20,956$15.03$314,968.68319,083View SEC Filing  
6/5/2017Yoram PaltiInsiderSell3,825$13.82$52,861.50View SEC Filing  
6/2/2017Yoram PaltiInsiderSell8,000$13.27$106,160.007,825View SEC Filing  
5/31/2017Yoram PaltiInsiderSell8,000$12.49$99,920.0015,825View SEC Filing  
5/26/2017Yoram PaltiInsiderSell8,000$12.88$103,040.0023,825View SEC Filing  
5/24/2017Yoram PaltiInsiderSell4,000$13.15$52,600.0029,256View SEC Filing  
5/23/2017Yoram PaltiInsiderSell8,000$11.73$93,840.0035,825View SEC Filing  
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.0043,825View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.0047,825View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.0055,825View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.0063,825View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.0071,825View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.0079,825View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.0087,825View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.0095,825View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00103,825View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00111,825View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00119,825View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00127,825View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00143,825View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00143,825View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00143,825View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00143,825View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.006,125,000View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00139,084View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00179,084View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00179,084View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00219,084View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00259,084View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00289,084View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00299,084View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00309,084View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60676,576View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00324,084View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00933,557View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00148,114View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NovoCure (NASDAQ NVCR) News Headlines

Source:
DateHeadline
NovoCure (NVCR) Given Consensus Recommendation of "Buy" by AnalystsNovoCure (NVCR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 7:48 AM
BRIEF-Novocure Says Executive Chairman William Doyles FY 2017 Total Compensation Was $23.8 MlnBRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
www.reuters.com - April 20 at 5:30 PM
NovoCure (NVCR) Insider Sells $1,042,302.80 in StockNovoCure (NVCR) Insider Sells $1,042,302.80 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM
NovoCure (NVCR) COO Sells $921,200.00 in StockNovoCure (NVCR) COO Sells $921,200.00 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM
NovoCure (NVCR) Upgraded at Deutsche BankNovoCure (NVCR) Upgraded at Deutsche Bank
www.americanbankingnews.com - April 19 at 10:01 AM
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...
globenewswire.com - April 19 at 8:07 AM
Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in MesotheliomaBlog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma
finance.yahoo.com - April 19 at 8:07 AM
Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 19 at 8:07 AM
NovoCure (NVCR) Set to Announce Quarterly Earnings on ThursdayNovoCure (NVCR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:34 AM
NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in SessionNovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
finance.yahoo.com - April 18 at 5:53 PM
NovoCure (NVCR) Receives Buy Rating from MizuhoNovoCure (NVCR) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 18 at 9:00 AM
BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In MesotheliomaBRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma
www.reuters.com - April 17 at 6:06 PM
NovoCure (NVCR) Downgraded by BidaskClub to "Buy"NovoCure (NVCR) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 1:54 PM
Whats Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage MedicalWhat's Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage Medical
www.prnewswire.com - April 17 at 8:16 AM
Novocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in MesotheliomaNovocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
www.streetinsider.com - April 17 at 8:16 AM
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in MesotheliomaNovocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
finance.yahoo.com - April 17 at 8:16 AM
NovoCure (NVCR) Expected to Announce Quarterly Sales of $56.79 MillionNovoCure (NVCR) Expected to Announce Quarterly Sales of $56.79 Million
www.americanbankingnews.com - April 17 at 3:28 AM
 Analysts Anticipate NovoCure (NVCR) Will Announce Earnings of -$0.13 Per Share Analysts Anticipate NovoCure (NVCR) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 15 at 1:23 PM
BidaskClub Upgrades NovoCure (NVCR) to Strong-BuyBidaskClub Upgrades NovoCure (NVCR) to Strong-Buy
www.americanbankingnews.com - April 14 at 9:51 PM
NovoCure (NVCR) Downgraded by Zacks Investment ResearchNovoCure (NVCR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 14 at 6:54 PM
Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual MeetingData on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 13 at 5:41 PM
Insider Selling: NovoCure (NVCR) Insider Sells 60,000 Shares of StockInsider Selling: NovoCure (NVCR) Insider Sells 60,000 Shares of Stock
www.americanbankingnews.com - April 4 at 10:39 PM
Novocure (NVCR) Stock Rating Upgraded by Zacks Investment ResearchNovocure (NVCR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:54 PM
Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet A Threat To Its Future?Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet A Threat To Its Future?
finance.yahoo.com - April 3 at 5:43 PM
Novocure to Report First Quarter 2018 Financial ResultsNovocure to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 3 at 8:10 AM
Insider Selling: Novocure Ltd (NVCR) CTO Sells 30,000 Shares of StockInsider Selling: Novocure Ltd (NVCR) CTO Sells 30,000 Shares of Stock
www.americanbankingnews.com - April 2 at 4:14 PM
Zacks: Brokerages Expect Novocure Ltd (NVCR) Will Announce Quarterly Sales of $56.79 MillionZacks: Brokerages Expect Novocure Ltd (NVCR) Will Announce Quarterly Sales of $56.79 Million
www.americanbankingnews.com - March 31 at 2:28 AM
-$0.13 EPS Expected for Novocure Ltd (NVCR) This Quarter-$0.13 EPS Expected for Novocure Ltd (NVCR) This Quarter
www.americanbankingnews.com - March 29 at 5:23 PM
Novocure Ltd (NVCR) Receives Consensus Rating of "Buy" from AnalystsNovocure Ltd (NVCR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 10:17 AM
Contrasting Helios and Matheson Analytics (HMNY) & Novocure (NVCR)Contrasting Helios and Matheson Analytics (HMNY) & Novocure (NVCR)
www.americanbankingnews.com - March 27 at 9:18 PM
BRIEF-NCCN Guidelines Recommend Novocures Optune In Combination With TemozolomideBRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide
www.reuters.com - March 20 at 5:25 PM
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed GlioblastomaNCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
finance.yahoo.com - March 20 at 5:25 PM
Active-Investors: Wired News - NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018Active-Investors: Wired News - NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018
www.finanznachrichten.de - March 19 at 5:26 PM
Wired News – NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018Wired News – NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018
finance.yahoo.com - March 19 at 8:10 AM
Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)
finance.yahoo.com - March 15 at 6:24 PM
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - March 15 at 8:06 AM
Novocure (NVCR) Stock Rating Upgraded by BidaskClubNovocure (NVCR) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 4:59 PM
Analyzing Madrigal Pharmaceuticals (MDGL) and Novocure (NVCR)Analyzing Madrigal Pharmaceuticals (MDGL) and Novocure (NVCR)
www.americanbankingnews.com - March 8 at 2:24 PM
1,055,000 Shares in Novocure Ltd (NVCR) Acquired by Tamarack Advisers LP1,055,000 Shares in Novocure Ltd (NVCR) Acquired by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:31 AM
Novocure Ltd (NVCR) Receives Average Recommendation of "Buy" from BrokeragesNovocure Ltd (NVCR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 3 at 12:16 PM
EAM Investors LLC Buys New Stake in Novocure Ltd (NVCR)EAM Investors LLC Buys New Stake in Novocure Ltd (NVCR)
www.americanbankingnews.com - March 1 at 12:10 PM
Novocure (NVCR) Raised to Hold at Zacks Investment ResearchNovocure (NVCR) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 28 at 10:52 AM
Tumor-treating biotech Novocure turns its attention to lu...Tumor-treating biotech Novocure turns its attention to lu...
finance.yahoo.com - February 27 at 6:02 PM
Cramer Remix: It's time to investigate risky VIX-related trading productsCramer Remix: It's time to investigate risky VIX-related trading products
finance.yahoo.com - February 27 at 6:02 PM
Novocure Ltd (NVCR) Position Boosted by Cortina Asset Management LLCNovocure Ltd (NVCR) Position Boosted by Cortina Asset Management LLC
www.americanbankingnews.com - February 27 at 1:40 PM
Novocure Sees Unusually High Options Volume (NVCR)Novocure Sees Unusually High Options Volume (NVCR)
www.americanbankingnews.com - February 27 at 8:38 AM
Medical Equipment Stocks Research Reports Released on Nevro, NovoCure, NuVasive, and Nxstage Medical - PR Newswire (press release)Medical Equipment Stocks' Research Reports Released on Nevro, NovoCure, NuVasive, and Nxstage Medical - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:08 AM
Michael J. Ambrogi Sells 8,458 Shares of Novocure Ltd (NVCR) StockMichael J. Ambrogi Sells 8,458 Shares of Novocure Ltd (NVCR) Stock
www.americanbankingnews.com - February 26 at 6:50 PM
Novocure Ltd (NVCR) General Counsel Sells $130,699.53 in StockNovocure Ltd (NVCR) General Counsel Sells $130,699.53 in Stock
www.americanbankingnews.com - February 26 at 6:50 PM
Novocure Ltd (NVCR) CFO Sells $264,750.33 in StockNovocure Ltd (NVCR) CFO Sells $264,750.33 in Stock
www.americanbankingnews.com - February 26 at 6:34 PM

SEC Filings

NovoCure (NASDAQ:NVCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NovoCure (NASDAQ:NVCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NovoCure (NASDAQ NVCR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.